Core Viewpoint - China Tongru (01763) has made a significant breakthrough in the field of stable isotopes by launching carbon isotope products, marking China's advancement in high-end technology and reducing reliance on imports for key medical materials [1] Group 1: Product Launch and Significance - The launch of high-abundance 13CO gas and carbon-13 urea raw materials positions China as one of the few countries capable of producing these essential components for medical applications [1] - The new products will eliminate China's complete dependence on imports for 13CO used in urea breath tests for detecting Helicobacter pylori infections, enhancing domestic production capabilities [1] Group 2: Industry Impact and Future Projects - The announcement coincides with the initiation of the second phase of the stable isotope base project, which will ensure a stable supply of high-abundance 13CO gas and other raw materials for gastrointestinal disease treatments [1] - This development is expected to significantly contribute to national health improvement and the high-quality development of medical isotopes, aligning with the "Healthy China" initiative [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 1 當日，中國同輻正式啟動穩定同位素基地二期項目建設，項目建成後，中國同輻 將形成高豐度13CO氣體、碳13尿素原料藥以及其它覆蓋胃腸道疾病治療藥物原 料藥的穩定供應能力，對提升國民健康水平、促進醫用同位素高質量發展、服務 「健康中國」建設具有重要意義。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年10月31日 自願性公告 中國同輻突破呼氣診斷關鍵原料技術 成為完整掌握呼氣試驗產品全產業鏈的龍頭企業 本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 本公司董事會（「董事會」）欣然宣佈，10月31日，中國同輻發佈碳同位素產品，標 誌着我國在穩定同位素領 ...

Core Viewpoint - The 2024 Golden Bull Award for Dividend Return was awarded to Huate Dain, a company focused on the pharmaceutical industry, emphasizing its commitment to children's health and high-quality development [1][2]. Group 1: Event Overview - The 2025 High-Quality Development Forum for Listed Companies and the 27th Golden Bull Award Ceremony took place in Nantong, Jiangsu on October 29 [1]. - The theme of the forum was "Moving Forward with New Initiatives, Achieving Long-Term Goals through Practical Actions, and Innovating for the Future" [1]. Group 2: Award Details - The Golden Bull Award is a prestigious evaluation activity organized by China Securities Journal, established in 1999, focusing on transparency and professionalism [1]. - This year's awards included nine categories, such as "Most Investment Value Award," "Golden Bull Listed Company Dividend Return Award," and "Golden Bull Secretary Award" [2]. - The "Golden Bull Listed Company Dividend Return Award" was based on key indicators like total dividends, dividend yield, and frequency of dividends over recent years, resulting in the recognition of 60 listed companies [2].

Group 1 - The core viewpoint of the article highlights the successful issuance of a three-year technology innovation bond by North China Pharmaceutical Co., Ltd., led by the Shijiazhuang branch of Industrial Bank, with a total issuance scale of 500 million yuan [1] - This bond issuance marks the first technology innovation bond in the pharmaceutical industry of Hebei Province, setting a historical low for the interest rate of similar products in the region [1] - The funds raised will provide strong financial support for the company's key technological innovation areas, accelerating the transformation and implementation of innovative results [1] Group 2 - As of September 2025, the Shijiazhuang branch of Industrial Bank has provided over 20 billion yuan in financing support to enterprises in Hebei through investment banking services [2] - The branch has served 15 technology-based enterprises through various services, including non-financial bond underwriting, merger loans, and syndicate loans [2] - The bank plans to deepen its "commercial bank + investment bank" strategy, focusing on the full-cycle needs of technology innovation enterprises and leveraging specialized products like technology innovation bonds to inject stable financial momentum into these companies [2]

Group 1 - The core point of the news is that Jimin Health (SH 603222) announced the release of 17.64 million shares from pledge by its major shareholder, Shuangge Group, which holds approximately 123 million shares, accounting for 23.38% of the total share capital [1] - After the release of the pledge, Shuangge Group has a total of 76.5 million shares pledged, which is 62.32% of its holdings and 14.57% of the total share capital [1] - The combined shareholding of Shuangge Group and its concerted parties is about 229 million shares, representing 43.52% of the total share capital [1] Group 2 - As of the announcement, Jimin Health's market capitalization is 5.4 billion yuan [2] - For the first half of 2025, Jimin Health's revenue composition is as follows: 52.07% from the pharmaceutical manufacturing sector, 46.01% from the medical services sector, 1.54% from pharmaceutical trading, and 0.38% from other businesses [1]

Group 1: Company Performance Overview - The company achieved double-digit growth in new orders for Q3, with an acceleration compared to the first half of the year [2] - The new business segments, including chemical and biological macromolecule businesses, are showing strong growth, indicating a positive revenue outlook for 2026 [2] Group 2: Capacity and Capital Expenditure - The capital expenditure for 2025 is projected to increase to approximately 1.3-1.4 billion, focusing on new business areas [3] - The small molecule business is experiencing tight capacity, particularly in Tianjin, while the Northeast facility is operating at normal utilization levels [3] - The company is expanding its capacity in the chemical macromolecule sector, with significant growth expected in the peptide and oligonucleotide businesses [3] Group 3: Profitability and Margins - The gross margin for new business segments reached 30.6% in the first three quarters of 2025, an increase of 10.6 percentage points year-on-year [4] - The domestic business revenue is expected to continue increasing, driven by a competitive domestic market and ongoing projects [5] - The company is implementing cost control measures to ensure that expense growth remains below revenue growth [6] Group 4: Market Trends and Future Outlook - The company anticipates a revenue growth of 13%-15% for the full year 2025, with increasing growth rates expected in 2026 and 2027 [4] - The domestic revenue share is expected to rise, supported by the increasing number of projects going overseas [5] - The company is focusing on enhancing its capabilities to capture more collaboration opportunities in the rapidly growing new molecule sector [4] Group 5: Competitive Positioning - The company’s core competencies lie in its delivery capabilities and investment in new technologies aimed at significantly reducing production costs [7] - The revenue structure of the chemical macromolecule business shows over 50% coming from peptide business, with a shift towards overseas markets expected [8]

Core Insights - The company reported a decline in revenue for its medical services segment, with a total of 2.018 billion yuan, representing a year-on-year decrease of 13.88% due to adjustments in medical insurance payment policies [2] - The gross profit margin for the medical services segment improved by 1.1 percentage points year-on-year, attributed to structural adjustments and cost management efforts [2] - The pharmaceutical segment experienced a significant revenue drop to 238 million yuan, down 60.46% year-on-year, primarily due to the impact of centralized procurement on the pricing and sales volume of its unique product series, resulting in losses for the segment [2]

Market Overview - A-shares experienced a style switch with individual stocks rising while major indices fell, indicating market divergence [1] - On October 31, the three major indices saw declines: Shanghai Composite Index down 0.81%, Shenzhen Component Index down 1.14%, and ChiNext Index down 2.31% [1] - Despite the index declines, 3,760 stocks rose, with 76 hitting the daily limit up, while 1,553 stocks fell [1] Sector Performance - AI application stocks showed strength against the market trend, with Fushi Holdings hitting the daily limit up [2] - Pharmaceutical stocks collectively surged, with companies like Shuotai Shen and Lianhuan Pharmaceutical reaching the daily limit up [3] - The lithium battery sector continued its upward trend, with companies such as Enjie and Tianji shares hitting the daily limit up [4] - Conversely, computing hardware stocks like Tianfu Communication and Zhongji Xuchuang saw declines of over 7% [5] - Storage chip concept stocks weakened, reflecting a broader trend of performance divergence in the market [6] Notable Events - A viral moment occurred when NVIDIA CEO Jensen Huang was seen dining with South Korean business leaders, leading to significant stock price increases for related companies [7] - Although Kkanbu Chicken is not publicly listed, its competitor Kyochon F&B's stock surged by 20%, and Cherrybro's stock hit the daily limit up with a 30% increase [7] - This incident highlights the impact of cultural and social media trends on stock performance, often overshadowing fundamental analysis [7] Strategic Developments - NVIDIA announced a milestone agreement with major South Korean companies to provide over 260,000 accelerator chips to enhance AI infrastructure in Korea [9] - The South Korean government is developing a "sovereign AI" initiative, deploying over 50,000 NVIDIA chips in data centers, including a national AI computing center [9] - Samsung Electronics plans to build an "AI factory" equipped with over 50,000 NVIDIA chips, while Hyundai will utilize NVIDIA processors for AI model development [10] - SK Group is set to establish Asia's first "industrial AI cloud" using NVIDIA RTX Pro 6000 Blackwell server chips for real-world AI applications [10]

Group 1 - Shutaishen announced preliminary results of STSA-1002 injection in clinical trials for Acute Respiratory Distress Syndrome (ARDS) [2] - Zhongsheng Pharmaceutical's subsidiary received approval for innovative drug Anladiwei tablets for treating adult influenza, with plans to redirect 103 million yuan for new drug development targeting overweight/diabetic and influenza populations [2] - Haisike's main products include small and large volume injections, powder injections, and solid preparations [2] Group 2 - Lithium hexafluorophosphate prices continue to rise [2] - Tianji shares have seen a rapid increase, with the company being a leading producer of lithium hexafluorophosphate, focusing on solid-state battery technology [2] - Guancheng New Materials reported a turnaround in net profit for the first three quarters [2] Group 3 - Hongyuan Green Energy, a leading domestic photovoltaic silicon wafer company, reported a net profit of 235.3 million yuan for the third quarter, marking a return to profitability [3] - Litong Electronics' net profit increased by 309.76% year-on-year, driven by growth in computing power and manufacturing businesses [3] - Yaxiang Integration reported a net profit of 442.5 million yuan for the third quarter, significantly up from the previous quarter [3] Group 4 - Wind God Co., a subsidiary of China National Chemical Corporation, reported a 168% increase in net profit for the third quarter [4] - Yatong Precision reported a staggering 1125% increase in net profit for the third quarter [4] - Dazhong Public reported a 205.14% increase in net profit for the first three quarters [4] Group 5 - Youfu Food, a well-known brand in the bubble chicken feet sector, reported a 43.34% increase in net profit for the first three quarters [9] - Richen Electronics reported a 309.76% increase in net profit, with a focus on computing power and manufacturing [9] - Aokang International, a leading domestic leather shoe brand, has a strong market presence with its various product lines [9]

Market Overview - On October 31, A-shares experienced a divergence where the three major indices fell, with the Shanghai Composite Index down 0.81%, the Shenzhen Component down 1.14%, and the ChiNext Index down 2.31. However, nearly 4,000 companies saw their stock prices rise, indicating a market where individual stocks performed well despite overall index declines [1][3]. Stock Performance - A total of 76 stocks hit the daily limit up, while 148 stocks rose more than 7%. The overall increase in stock prices was 38.13%, with a total trading volume of approximately 23498.13 billion [3]. - The AI application sector showed resilience against the market downturn, with stocks like Fushi Holdings hitting the daily limit up [3]. - Pharmaceutical stocks collectively surged, with companies like Shutai Shen and Lianhuan Pharmaceutical reaching their daily limits [5]. Sector Analysis - The lithium battery sector continued its upward trend, with stocks such as Enjie Co. and Tianji Co. hitting the daily limit up [6]. - In contrast, CPO and computing hardware stocks faced adjustments, with companies like Tianfu Communication and Zhongji Xuchuang dropping over 7% [6][7]. - The recent trend showed that stocks with declining performance, particularly in the liquor industry, experienced a rebound despite poor earnings reports, while technology stocks faced significant declines [8][9]. Notable Events - A viral moment occurred when NVIDIA CEO Jensen Huang was seen dining with prominent South Korean business leaders, leading to a surge in related stocks. For instance, Kyochon F&B's stock price soared by 20%, and Cherrybro's stock hit the daily limit up with a 30% increase [12][14]. - NVIDIA announced a significant agreement with major South Korean companies to provide over 260,000 accelerator chips to support AI projects, marking a strategic expansion in AI infrastructure [20][21].